MAM-36 and ABILHAND as outcome measures of multiple sclerosis hand disability: an observational study

被引:1
|
作者
Prada, Valeria [1 ]
Tacchino, Andrea [2 ]
Podda, Jessica [2 ]
Pedulla, Ludovico [3 ]
Konrad, Giovanna [3 ]
Battaglia, Mario A. [4 ]
Brichetto, Giampaolo [2 ,3 ]
Monti Bragadin, Margherita [2 ,3 ]
机构
[1] Univ Genoa, Dept Neurosci, Genet & Maternal & Infantile Sci DINOGMI, Ophthalmol,Rehabil, Genoa, Italy
[2] Italian Multiple Sclerosis Soc Res Fdn FISM, Genoa, Italy
[3] AISM Rehabil Ctr, Italian Multiple Sclerosis Soc, Genoa, Italy
[4] Univ Siena, Dept Physiopathol, Expt Med & Publ Hlth, Siena, Italy
关键词
Outcome assessment; health care; Multiple sclerosis; Upper extremity; Neurodegenerative diseases; QUALITY-OF-LIFE; MANUAL ABILITY; PSYCHOMETRIC VALIDATION; EXPANDED DISABILITY; STATUS SCALE; FATIGUE; HEALTH; QUESTIONNAIRE; IMPAIRMENT; DEXTERITY;
D O I
10.23736/S1973-9087.20.06446-1
中图分类号
R49 [康复医学];
学科分类号
100215 ;
摘要
BACKGROUND: Impaired upper limb functionality and dexterity are common in people with multiple sclerosis (PwMS) and lead to increased dependency and reduced quality of life. AIM: The aim of this study was to compare the ability of the Manual Abilites Measure 36 (MAM-36) and the ABILHAND questionnaire to recognize an involvement of the upper limbs in PwMS, and to compare their results with those of other patient reported outcomes (PRO) evaluating disability, functional independence, symptoms of anxiety and depression, fatigue and quality of life. DESIGN: The study design was observational. SETTING: The setting of the study was outpatient. POPULATION: The study population included fifty-one PwMS (mean age of 56.31 years, age range of 33-82 years, 72.5% of patients were females). METHODS: For each patient were collected MAM-36, ABILHAND questionnaire, expanded disability status scale (EDSS), Functional Independence measure (FIM), Hospital Anxiety and Depression Scale (HADS), Modified Fatigue Impact Scale (MFIS) and Life Satisfaction Index (LSI). RESULTS : A strong correlation between MAM-36 and the ABILHAND questionnaire (Spearman r: 0.79; P<0.0001) were found. We obtained a significant correlation between MAM-36 and EDSS (Spearman r: -0.5; P=0.0002), FIM (Spearman r: 0.55; P<0.0001); we did not observe a correlation with MFIS (Spearman r: -0.33; P=0.02); moreover we found a similar trend between ABILHAND and EDSS (Spearman r: -0.47; P=0.0005), FIM (Spearman r: 0.61; P<0.0001), MFIS (Spearman r: -0.41; P=0.002). CONCLUSIONS: In PwMS the assessment of upper limbs is fundamental since it closely related to the level of disability of the person. Both MAM-36 and ABILHAND Questionnaire are equally able to detect upper limb dysfunctions in PwMS. CLINICAL REHABILITATION IMPACT : Both MAM-36 and ABILHAND can be used for upper limbs evaluation, within a multidimensional approach that seems to be the best way to evaluate PwMS.
引用
收藏
页码:520 / 526
页数:7
相关论文
共 50 条
  • [1] Mam-36 and abilhand questionnaire as outcome measures of multiple sclerosis hand functional disability: an observational study
    Bragadin, Margherita Monti
    Prada, Valeria
    Podda, Jessica
    Pedulla, Ludovico
    Tacchino, Andrea
    Konrad, Giovanna
    Battaglia, Mario Alberto
    Brichetto, Giampaolo
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (2_SUPPL) : 45 - 45
  • [2] Cross-cultural adaptation and psychometric properties of the Turkish version of the Manual Ability Measure-36 (MAM-36) in people with multiple sclerosis
    Ozge Ertekin
    Turhan Kahraman
    Mona Aras
    Cavid Baba
    Serkan Ozakbas
    Neurological Sciences, 2021, 42 : 2927 - 2936
  • [3] Cross-cultural adaptation and psychometric properties of the Turkish version of the Manual Ability Measure-36 (MAM-36) in people with multiple sclerosis
    Ertekin, Ozge
    Kahraman, Turhan
    Aras, Mona
    Baba, Cavid
    Ozakbas, Serkan
    NEUROLOGICAL SCIENCES, 2021, 42 (07) : 2927 - 2936
  • [4] The administration of the paper and electronic versions of the Manual Ability Measure-36 (MAM-36) and Fatigue Severity Scale (FSS) is equivalent in people with multiple sclerosis
    Andrea Tacchino
    Rachele Di Giovanni
    Erica Grange
    Maria Marcella Spirito
    Michela Ponzio
    Mario Alberto Battaglia
    Giampaolo Brichetto
    Claudio Marcello Solaro
    Neurological Sciences, 2024, 45 : 1155 - 1162
  • [5] The administration of the paper and electronic versions of the Manual Ability Measure-36 (MAM-36) and Fatigue Severity Scale (FSS) is equivalent in people with multiple sclerosis
    Tacchino, Andrea
    Di Giovanni, Rachele
    Grange, Erica
    Spirito, Maria Marcella
    Ponzio, Michela
    Battaglia, Mario Alberto
    Brichetto, Giampaolo
    Solaro, Claudio Marcello
    NEUROLOGICAL SCIENCES, 2024, 45 (03) : 1155 - 1162
  • [6] Commentary on 'Disability outcome measures in multiple sclerosis clinical trials'
    Noble, J. Gareth
    Osborne, Lisa A.
    Jones, Kerina H.
    Middleton, Rod M.
    Ford, David V.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (12) : 1718 - 1720
  • [7] Italian translation and psychometric validation of the Manual Ability Measure-36 (MAM-36) and its correlation with an objective measure of upper limb function in patients with multiple sclerosis
    Claudio Solaro
    Rachele Di Giovanni
    Erica Grange
    Giampaolo Brichetto
    Margit Mueller
    Andrea Tacchino
    Rita Bertoni
    Francesco Patti
    Angelo Pappalardo
    Luca Prosperini
    Letizia Castelli
    Rosalba Rosato
    Davide Cattaneo
    Davide Marengo
    Neurological Sciences, 2020, 41 : 1539 - 1546
  • [8] Italian translation and psychometric validation of the Manual Ability Measure-36 (MAM-36) and its correlation with an objective measure of upper limb function in patients with multiple sclerosis
    Solaro, Claudio
    Di Giovanni, Rachele
    Grange, Erica
    Brichetto, Giampaolo
    Mueller, Margit
    Tacchino, Andrea
    Bertoni, Rita
    Patti, Francesco
    Pappalardo, Angelo
    Prosperini, Luca
    Castelli, Letizia
    Rosato, Rosalba
    Cattaneo, Davide
    Marengo, Davide
    NEUROLOGICAL SCIENCES, 2020, 41 (06) : 1539 - 1546
  • [9] Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis
    Bernard M. J. Uitdehaag
    CNS Drugs, 2018, 32 : 543 - 558
  • [10] Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis
    Uitdehaag, Bernard M. J.
    CNS DRUGS, 2018, 32 (06) : 543 - 558